ATP-noncompetitive CDK inhibitors for cancer therapy: an overview
Agnese Anna Abate1, Francesca Pentimalli, Luca Esposito
1Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA.
Introduction:
Cyclin-dependent kinases (CDKs) are the key drivers of cell cycle progression and are often deregulated in cancer, therefore, targeting CDKs has long been pursued as a therapeutic strategy to tackle cancer. Unfortunately, however, none of the first-generation CDK inhibitors has yielded the expected efficacy to be successfully translated to the clinic mostly because, by targeting the very conserved kinase ATP-binding site resulted to be poorly specific and quite toxic.
Areas Covered:
Here, the authors review recent approaches aimed at developing more specific CDK inhibitors mostly through the aid of computational drug design studies and report various small molecules and peptides, which resulted in promising CDK ATP-noncompetitive inhibitors.
Expert Opinion:
Despite few successes, these new approaches still need additional considerations to generate effective antitumoral agents. The authors discuss some of the hurdles to overcome for a successful clinical translation.
Insights
Targeting cyclin-dependent kinases (CDKs) for cancer therapy is challenging due to specificity issues. New computational approaches are exploring non-ATP-binding site inhibitors for improved efficacy and reduced toxicity.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Cyclin-dependent kinases (CDKs) are crucial regulators of cell cycle progression.
- CDK deregulation is common in cancer, making them attractive therapeutic targets.
- First-generation CDK inhibitors showed limited clinical success due to poor specificity and toxicity, stemming from targeting the conserved ATP-binding site.
Purpose of the Study:
- To review novel strategies for developing more specific CDK inhibitors.
- To highlight the role of computational drug design in this endeavor.
- To discuss the potential of ATP-noncompetitive inhibitors.
Main Methods:
- Review of recent literature on CDK inhibitor development.
- Focus on computational drug design approaches.
- Identification of small molecules and peptides targeting CDKs.
Main Results:
- Emergence of promising CDK ATP-noncompetitive inhibitors.
- Small molecules and peptides show potential as novel therapeutic agents.
- Computational drug design aids in identifying specific inhibitors.
Conclusions:
- New approaches offer promise for developing effective anti-cancer agents.
- Further research and considerations are needed for successful clinical translation.
- Overcoming hurdles in clinical translation remains a key challenge.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:34Inhibition of CDK Activity
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...